A Randomized Phase II Study of Fulvestrant in Combination with the dual mTOR Inhibitor AZD2014 or Everolimus or Fulvestrant alone in Estrogen Receptor-Positive Advanced or Metastatic Breast Cancer

Trial Profile

A Randomized Phase II Study of Fulvestrant in Combination with the dual mTOR Inhibitor AZD2014 or Everolimus or Fulvestrant alone in Estrogen Receptor-Positive Advanced or Metastatic Breast Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Apr 2017

At a glance

  • Drugs Fulvestrant (Primary) ; Vistusertib (Primary) ; Everolimus
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms MANTA
  • Most Recent Events

    • 12 Dec 2015 Trial design presented at the 38th Annual San Antonio Breast Cancer Symposium.
    • 11 Dec 2015 Accrual to date is 59% according to the United Kingdom Clinical Research Network record.
    • 04 Oct 2015 Accrual to date is 50% according to the United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top